RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
…
Rockwood Research

Corporate filings · Event Monitor · Free for all

← Back

Relay Therapeutics, Inc.

RLAY

Biological Products, (No Diagnostic Substances) · SIC 2836 · CIK 0001812364

SHARE:XLINKEDINEMAIL
Revenue FY2025
$15.0M
Net Income
$(276.0M)
EPS (Basic)
$-1.61
Net Margin
-1800.6%
ROE
-48.8%
Total Equity
$567.0M
Shares Out
219M

Relay Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Revenue & Net Income (10Y)

Margin Trends

Investor Ownership · 5 funds in our universe

FundPosition Value% of AUMQoQ ChgWeight
Baker Bros. Advisors
Baker Bros. Advisors
$52.9M
0.2%
+143.7%
Duquesne Family Office
Stanley Druckenmiller
$6.5M
0.1%
NEW
Adage Capital Management
Adage Capital Management
$32.6M
0.0%
(32.8%)
Alps Advisors
Alps Advisors
$4.1M
0.0%
+51.5%
ICONIQ Capital
ICONIQ Capital
$1.8M
0.0%
—

Insider Transactions

Reading stored insider transactions…